PH12022552003A1 - Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof - Google Patents
Nonalcoholic steatohepatitis (nash) biomarkers and uses thereofInfo
- Publication number
- PH12022552003A1 PH12022552003A1 PH1/2022/552003A PH12022552003A PH12022552003A1 PH 12022552003 A1 PH12022552003 A1 PH 12022552003A1 PH 12022552003 A PH12022552003 A PH 12022552003A PH 12022552003 A1 PH12022552003 A1 PH 12022552003A1
- Authority
- PH
- Philippines
- Prior art keywords
- nash
- biomarkers
- nonalcoholic steatohepatitis
- subject
- hepatic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972418P | 2020-02-10 | 2020-02-10 | |
| PCT/US2021/017217 WO2021163034A1 (en) | 2020-02-10 | 2021-02-09 | Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552003A1 true PH12022552003A1 (en) | 2024-02-05 |
Family
ID=74858782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552003A PH12022552003A1 (en) | 2020-02-10 | 2021-02-09 | Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230071234A1 (https=) |
| EP (1) | EP4103948A1 (https=) |
| JP (2) | JP7766605B2 (https=) |
| KR (1) | KR20220140727A (https=) |
| CN (1) | CN115066616A (https=) |
| AU (1) | AU2021220787A1 (https=) |
| BR (1) | BR112022015303A2 (https=) |
| CA (2) | CA3300793A1 (https=) |
| IL (1) | IL295064A (https=) |
| MX (1) | MX2022009517A (https=) |
| PH (1) | PH12022552003A1 (https=) |
| WO (1) | WO2021163034A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023238881A1 (ja) * | 2022-06-07 | 2023-12-14 | 日東電工株式会社 | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー |
| WO2025090996A1 (en) * | 2023-10-28 | 2025-05-01 | Novelna Inc. | Nafld detection proteins and methods of use thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US7855054B2 (en) | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7824871B2 (en) * | 2007-06-14 | 2010-11-02 | George Mason Intellectual Properties | Methods of diagnosing non-alcoholic steatohepatitis (NASH) |
| CN101802225B (zh) | 2007-07-17 | 2013-10-30 | 私募蛋白质体公司 | 检测样品的多元分析 |
| JP5781436B2 (ja) * | 2008-08-11 | 2015-09-24 | バンヤン・バイオマーカーズ・インコーポレーテッド | 神経学的状態のバイオマーカー検出方法およびアッセイ |
| SG186953A1 (en) | 2010-07-09 | 2013-02-28 | Somalogic Inc | Lung cancer biomarkers and uses thereof |
| CN103429753A (zh) | 2010-09-27 | 2013-12-04 | 私募蛋白质体公司 | 间皮瘤生物标记及其用途 |
| WO2014150198A2 (en) * | 2013-03-15 | 2014-09-25 | Somalogic, Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| GB201320061D0 (en) * | 2013-11-13 | 2013-12-25 | Electrophoretics Ltd | Materials nad methods for diagnosis and prognosis of liver cancer |
| EP3110976B1 (en) * | 2014-02-27 | 2020-05-13 | Biogen MA Inc. | Method of assessing risk of pml |
| CA2978696A1 (en) * | 2015-02-03 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Novel methods for early identification of bone healing ability in injured patients |
| EP3303629A1 (en) * | 2015-06-05 | 2018-04-11 | Regulus Therapeutics Inc. | Non-alcoholic fatty liver disease biomarkers |
| KR20180029046A (ko) * | 2015-06-19 | 2018-03-19 | 세라 프로그노스틱스 인코포레이티드 | 조산 예측용 바이오마커 쌍 |
| CN107923918A (zh) * | 2015-09-09 | 2018-04-17 | 私募蛋白质体公司 | 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法 |
| US20210215711A1 (en) * | 2016-02-08 | 2021-07-15 | Somalogic, Inc. | Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof |
| US9725769B1 (en) * | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| CN111183360B (zh) * | 2017-07-19 | 2024-10-18 | 生物辐射欧洲有限公司 | 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合 |
-
2021
- 2021-02-09 KR KR1020227027222A patent/KR20220140727A/ko active Pending
- 2021-02-09 WO PCT/US2021/017217 patent/WO2021163034A1/en not_active Ceased
- 2021-02-09 EP EP21710121.1A patent/EP4103948A1/en active Pending
- 2021-02-09 MX MX2022009517A patent/MX2022009517A/es unknown
- 2021-02-09 PH PH1/2022/552003A patent/PH12022552003A1/en unknown
- 2021-02-09 BR BR112022015303A patent/BR112022015303A2/pt unknown
- 2021-02-09 IL IL295064A patent/IL295064A/en unknown
- 2021-02-09 US US17/796,748 patent/US20230071234A1/en active Pending
- 2021-02-09 CA CA3300793A patent/CA3300793A1/en active Pending
- 2021-02-09 CN CN202180012807.5A patent/CN115066616A/zh active Pending
- 2021-02-09 JP JP2022547788A patent/JP7766605B2/ja active Active
- 2021-02-09 AU AU2021220787A patent/AU2021220787A1/en active Pending
- 2021-02-09 CA CA3166923A patent/CA3166923A1/en active Pending
-
2025
- 2025-10-28 JP JP2025181395A patent/JP2026021411A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3166923A1 (en) | 2021-08-19 |
| JP2023512701A (ja) | 2023-03-28 |
| IL295064A (en) | 2022-09-01 |
| US20230071234A1 (en) | 2023-03-09 |
| KR20220140727A (ko) | 2022-10-18 |
| AU2021220787A1 (en) | 2022-09-01 |
| CN115066616A (zh) | 2022-09-16 |
| BR112022015303A2 (pt) | 2022-09-27 |
| JP2026021411A (ja) | 2026-02-10 |
| WO2021163034A1 (en) | 2021-08-19 |
| EP4103948A1 (en) | 2022-12-21 |
| CA3300793A1 (en) | 2026-03-02 |
| MX2022009517A (es) | 2022-09-02 |
| JP7766605B2 (ja) | 2025-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552003A1 (en) | Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof | |
| PH12022553269A1 (en) | Composition, kit and method for detecting sars-cov-2 and use thereof | |
| PL2012822T3 (pl) | Zmodyfikowane białko heksonu adenowirusa i jego zastosowania | |
| MX387070B (es) | Metodo para tratar fibrosis hepatica | |
| MX2025005441A (es) | Composiciones de inoculantes microbianos y metodos relacionados | |
| WO2005047524A3 (en) | Compositions and methods for inducing cell dedifferentiation | |
| WO2007040862A3 (en) | System and method for determining a presence state of a user | |
| MX2010009160A (es) | Composicion de limpieza que proporciona beneficios residuales. | |
| PT1420769E (pt) | Modulação de perfil lipídico com esteróides e agonistas de ppar alfa | |
| MY150643A (en) | Methods and compositions for targeting hepsin | |
| IL325494A (en) | Methods and biomarkers for liver fibrosis, nonalcoholic steatohepatitis and risk thereof | |
| WO2001089225A3 (en) | Image foreground/background velocity detector | |
| EP1127580A3 (en) | Method of increasing the bioavailability and tissue penetration of azithromycin | |
| WO2006093797A3 (en) | Method and kit for detecting porcine reproductive and respiratory syndrome virus | |
| WO2005028621A3 (en) | Assays with primary cells | |
| WO2006096735A3 (en) | Enhancing a luminescent signal | |
| TW200719881A (en) | Sedative effect-enabling agent and sedative aroma composition comprising the same | |
| WO2007024762A3 (en) | Lined envelope | |
| WO2019161211A3 (en) | Compositions and methods for the reduction or prevention of hepatic steatosis and nash | |
| TW200716130A (en) | Purified form of tanaproget | |
| AU2003303347A1 (en) | Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs | |
| WO2006124872A3 (en) | Methods for determining contamination of fluid compositions | |
| TW200622984A (en) | Plasma display device and method for driving the same | |
| CA3296449A1 (en) | Liver fibrosis, nash and "at-risk" nash biomarkers and methods | |
| EP4092051A4 (en) | SOLUBLE ANTI-SUBTYPE CD14 ANTIBODY, KIT AND CORRESPONDING USE |